首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

1675282

2025 年至 2033 年憂鬱症藥物市場報告（依藥物類別、疾病類型、藥物類型、配銷通路和地區分類）

Depression Drugs Market Report by Drug Class, Disorder Type, Drug Type, Distribution Channel, and Region 2025-2033

出版日期: 2025年03月01日 | 出版商:

IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2024IMARC Group全球抗憂鬱藥物市場規模達到 192 億美元。由於久坐的生活方式和壓力導致大眾抑鬱症病例不斷增加，藥物配方和給藥技術的不斷進步，以及對行動應用程式和線上治療平台等數位療法的偏好日益增加，這些都是推動市場成長的一些因素。

憂鬱症是一種精神障礙，其特徵是缺乏正面情緒，情緒持續低落，並出現許多認知、身體、行為和情緒症狀。診斷是透過識別症狀和檢查患者的病史來實現的。然後使用憂鬱藥物進行治療，該藥物可以平衡大腦中神經傳導物質（如血清素）的功能並控制患者的情緒和情緒。這些藥物可以幫助緩解焦慮、季節性情感障礙和心境惡劣障礙的症狀。

根據世界衛生組織 (WHO) 的數據，憂鬱症是導致殘疾的主要原因之一，影響了全球超過 2.64 億人。社交焦慮和憂鬱等精神障礙的盛行率不斷上升，這是推動憂鬱藥物市場成長的關鍵因素之一。此外，由於各國政府實施全面封鎖並推動社交疏離措施，相當一部分人口的日常生活發生了改變，進而對個人的心理健康產生了負面影響。這一趨勢已成為推動抗憂鬱藥物銷售的另一個重要成長因素。此外，隨著開發副作用小、效果持久的抗憂鬱藥物的新技術的出現，以及新藥的接受度不斷提高，預計將在未來幾年推動市場成長。

IMARC 集團的最新報告對全球抗憂鬱藥物市場進行了深入分析，涵蓋了其所有重要方面。內容涵蓋從市場的宏觀概況到行業表現的微觀細節、最新趨勢、關鍵市場促進因素和挑戰、 SWOT 分析、波特五力分析、價值鏈分析等。

本報告解答的關鍵問題

全球抗憂鬱藥物市場規模有多大？ COVID-19 對全球抗憂鬱藥物市場有何影響？
全球抗憂鬱藥物市場的預期成長率是多少？
推動全球抗憂鬱藥物市場發展的關鍵因素有哪些？
根據疾病類型，全球抗憂鬱藥物市場如何分佈？
根據配銷通路，全球抗憂鬱藥物市場的分佈是如何的？
全球抗憂鬱藥物市場的主要區域有哪些？
全球抗憂鬱藥物市場的關鍵公司/參與者有哪些？

The global depression drugs market size reached USD 19.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.1 Billion by 2033, exhibiting a growth rate (CAGR) of 2.9% during 2025-2033. The growing cases of depression among the masses due to sedentary lifestyle and stress, increasing advancements in drug formulation and delivery techniques, and rising preferences for digital therapeutics, such as mobile apps and online therapy platforms, are some of the factors impelling the market growth.

Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.

According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years.

IMARC Group's latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Key Market Segmentation:

Breakup by Drug Class:

Atypical Antipsychotics
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Selective Serotonin Reuptake Inhibitors (SSRIs)
Central Nervous System (CNS) Stimulants
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Others

Breakup by Disorder Type:

Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others

Breakup by Drug Type:

Generic Drugs
Branded Drugs

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Breakup by Region:

North America
Europe
Asia Pacific
Middle East and Africa
Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Key Questions Answered in This Report

1.What is the size of the global depression drugs market?
2.What has been the impact of COVID-19 on the global depression drugs market?
3.What is the expected growth rate of the global depression drugs market?
4.What are the key factors driving the global depression drugs market?
5.What is the breakup of the global depression drugs market based on the disorder type?
6.What is the breakup of the global depression drugs market based on the distribution channel?
7.What are the key regions in the global depression drugs market?
8.Who are the key companies/players in the global depression drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Depression Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Drug Class
5.5 Market Breakup by Disorder Type
5.6 Market Breakup by Drug Type
5.7 Market Breakup by Distribution Channel
5.8 Market Breakup by Region
5.9 Market Forecast

6 Market Breakup by Drug Class

6.1 Atypical Antipsychotics
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Central Nervous System (CNS) Stimulants
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Tricyclic Antidepressants
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Monoamine Oxidase Inhibitors
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
6.7 Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast

7 Market Breakup by Disorder Type

7.1 Major Depressive Disorder
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Obsessive-Compulsive Disorder
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Generalized Anxiety Disorder
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Panic Disorder
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by Drug Type

8.1 Generic Drugs
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Branded Drugs
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Europe
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Asia Pacific
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
10.4 Middle East and Africa
- 10.4.1 Market Trends
- 10.4.2 Market Forecast
10.5 Latin America
- 10.5.1 Market Trends
- 10.5.2 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porter's Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Otsuka Pharmaceutical
- 15.3.2 Pfizer
- 15.3.3 Eli Lilly and Company
- 15.3.4 AstraZeneca
- 15.3.5 Novartis
- 15.3.6 Bristol-Myers Squibb
- 15.3.7 GlaxoSmithKline
- 15.3.8 Takeda Pharmaceutical Company
- 15.3.9 Allergan
- 15.3.10 Johnson & Johnson
- 15.3.11 Zhejiang NHU Company Ltd
- 15.3.12 Sebela Pharmaceuticals

簡介目錄圖表

List of Figures

Figure 1: Global: Depression Drugs Market: Major Drivers and Challenges
Figure 2: Global: Depression Drugs Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Depression Drugs Market: Breakup by Drug Class (in %), 2024
Figure 4: Global: Depression Drugs Market: Breakup by Disorder Type (in %), 2024
Figure 5: Global: Depression Drugs Market: Breakup by Drug Type (in %), 2024
Figure 6: Global: Depression Drugs Market: Breakup by Distribution Channel (in %), 2024
Figure 7: Global: Depression Drugs Market: Breakup by Region (in %), 2024
Figure 8: Global: Depression Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 9: Global: Depression Drugs Industry: SWOT Analysis
Figure 10: Global: Depression Drugs Industry: Value Chain Analysis
Figure 11: Global: Depression Drugs Industry: Porter's Five Forces Analysis
Figure 12: Global: Depression Drugs (Atypical Antipsychotics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Depression Drugs (Atypical Antipsychotics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Depression Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Depression Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Depression Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Depression Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Depression Drugs (Major Depressive Disorder) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Depression Drugs (Major Depressive Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: Global: Depression Drugs (Generalized Anxiety Disorder) Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: Global: Depression Drugs (Generalized Anxiety Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: Global: Depression Drugs (Panic Disorder) Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: Global: Depression Drugs (Panic Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: Global: Depression Drugs (Other Disorder Types) Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: Global: Depression Drugs (Other Disorder Types) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: Global: Depression Drugs (Generic Drugs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: Global: Depression Drugs (Generic Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: Global: Depression Drugs (Branded Drugs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: Global: Depression Drugs (Branded Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: Global: Depression Drugs Market: Sales through Hospital Pharmacies (in Million USD), 2019 & 2024
Figure 41: Global: Depression Drugs Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2025-2033
Figure 42: Global: Depression Drugs Market: Sales through Retail Pharmacies (in Million USD), 2019 & 2024
Figure 43: Global: Depression Drugs Market Forecast: Sales through Retail Pharmacies (in Million USD), 2025-2033
Figure 44: Global: Depression Drugs Market: Sales through Online Pharmacies (in Million USD), 2019 & 2024
Figure 45: Global: Depression Drugs Market Forecast: Sales through Online Pharmacies (in Million USD), 2025-2033
Figure 46: Global: Depression Drugs Market: Sales through Other Distribution Channels (in Million USD), 2019 & 2024
Figure 47: Global: Depression Drugs Market Forecast: Sales through Other Distribution Channels (in Million USD), 2025-2033
Figure 48: North America: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: North America: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: Europe: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: Europe: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: Asia Pacific: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: Asia Pacific: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: Middle East and Africa: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: Middle East and Africa: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: Latin America: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: Latin America: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

Table 1: Global: Depression Drugs Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Depression Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
Table 3: Global: Depression Drugs Market Forecast: Breakup by Disorder Type (in Million USD), 2025-2033
Table 4: Global: Depression Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
Table 5: Global: Depression Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
Table 6: Global: Depression Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 7: Global: Depression Drugs Market Structure
Table 8: Global: Depression Drugs Market: Key Players

02-2729-4219

+886-2-2729-4219